5: Mass Spectrometry Challenges in Exenatide Characterization Exenatide is structurally smaller than semaglutide, but it still presents significant analytical complexities during GLP-1 Biosimilar Characterization
Capehorn MS, Catarig AM, Furberg JK et al (2020) Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
According to Grand View Research, specifically for GLP-1 weight-loss, the market size in 2025 is about $20.86 billion, expected to grow to $48.84 billion by 2030, with a CAGR of ~18.5%
so they should be managed accordingly." "Oh, I love that so much, Dr
, GLP-1
Simultaneous monitoring of cell number and metabolic activity of specific bacterial populations with a dual gfp-luxAB marker system